PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
29059199-8	2017	Among the beta-blockers, nadolol showed a significant risk reduction in both LQT1 and LQT2 (HR 0.47 and 0.27, respectively), whereas atenolol and propranolol decreased the risk only in LQT1 (HR 0.36 and 0.46, respectively).	Nadolol	25-32	potassium voltage-gated channel subfamily H member 2	Homo sapiens	86-90	
33611903-17	2021	Nadolol succeeded in eliminating cardiac events in one patient with LQT2 post ineffective metoprolol medication.	Nadolol	0-7	potassium voltage-gated channel subfamily H member 2	Homo sapiens	68-72	
33381033-5	2020	In conclusion, nadolol was recommended as a relatively effective strategy for LQT2 in order to improve the prognosis of patients during a long follow-up period.	Nadolol	15-22	potassium voltage-gated channel subfamily H member 2	Homo sapiens	78-82	
33304417-6	2020	This is the first report that demonstrates the efficacy and safety of trans-maternal administration of nadolol for treatment of symptomatic LQT2 fetuses with TdP.	Nadolol	103-110	potassium voltage-gated channel subfamily H member 2	Homo sapiens	140-144	
29059199-12	2017	Among them, nadolol was effective in LQT1 and LQT2, whereas other drugs showed different effectiveness depending on LQT genotype.	Nadolol	12-19	potassium voltage-gated channel subfamily H member 2	Homo sapiens	46-50	
34901807-1	2021	A novel frameshift mutation in the KCNH2 gene for long QT syndrome type 2 (LQTS2) was identified after torsades des pointes ventricular tachycardia in a 49-year-old patient managed with octreotide and nadolol for an acute variceal bleed.	Nadolol	201-208	potassium voltage-gated channel subfamily H member 2	Homo sapiens	35-40	
25257637-7	2014	In LQT1, the risk reduction for first cardiac events was similar among the 4 beta-blockers, but in LQT2, nadolol provided the only significant risk reduction (hazard ratio: 0.40 [0.16 to 0.98]).	Nadolol	105-112	potassium voltage-gated channel subfamily H member 2	Homo sapiens	99-103	
25257637-9	2014	CONCLUSIONS: Although the 4 beta-blockers are equally effective in reducing the risk of a first cardiac event in LQTS, their efficacy differed by genotype; nadolol was the only beta-blocker associated with a significant risk reduction in patients with LQT2.	Nadolol	156-163	potassium voltage-gated channel subfamily H member 2	Homo sapiens	252-256